A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck cancer compared with pembrolizumab alone

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517091-38-00

Acronym

1501-0002

Enrollment

Registered

2025-05-22

Start date

2025-11-25

Completion date

Unknown

Last updated

2025-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck squamous cell carcinoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria, France, Germany, Hungary, Italy, Poland, Romania, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026